Medivir logo

Medivir Investor Relations Material

Medivir AB researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Sweden and internationally. It focuses on targeted therapies and vaccines. The company offers Merivo alfa, a product that has completed late stage clinical trials; MIV-711, which has completed phase I/II clinical trials; MIV-102 that has completed phase I/II clinical trial; and other projects in various phases of clinical development. Medivir AB was founded in 1987 and is headquartered in Huddinge, Sweden

Upcoming events for

Q2 20222022-08-19
Q3 20222022-11-03

Latest company events

Ticker symbol

MVIR

Country

Sweden

Investor Relations Page

https://www.medivir.se/investerare

Dig deeper into the Medivir fundamentals on Quartr.

  • Skip straight to the Q&A session
  • Receive notifications about new events
  • Connect the financial calender on your phone
  • Figure out why the stock is up or down
  • Read the transcripts or scroll the deck
  • Access earnings or press releases
App store link
Android play link
Quartr app screenshot